IPC-USP 8th annual scientific meeting-India explores public health topics
Our News Bureau – Hyderabad
The 8th Annual Scientific Meet of the Indian Pharmacopoeia Commission (IPC) and the United States Pharmacopeia India was held in Hyderabad on February 11th and 12th, 2009. The Meeting featured an opening session, a special session on metal impurities, and a series of track sessions on pharmaceutical industry topics, including drug substances-adulterants and impurities, drug product manufacturing and control, microbiology, biologics and biotechnology as well as special tracks on reference standards and metal impurities.
Nearly 250 participants from more than 90 companies and organisations in India attended this meeting. In addition, exhibits and poster presentations were featured.
The meeting began with remarks from honoured guests, including Dr G N Singh, Secretary cum Scientific Director of the IPC from the Ministry of Health and Family Welfare, Dr Jayashree Gupta, Chairperson and Managing Director, IDPL, Ministry of Chemicals and Fertilizers, Dr Valerio Reggie, Executive Secretary, (IMPACT) of the World Health Organisation, and Dr Roger Williams, Chief Executive Officer, United States Pharmacopoeial Convention (USP).
Singh talked about the USP-IPC Memorandum of Understanding (MoU) and the prospect of strengthened partnering USP in the coming years. He talked about future laboratory development for the IPC, and the fact that IPC has released a 2008 Supplement to its 7th Edition issued in 2007.
In his remarks, Williams talked about the challenges facing the world and the pharma industry, the crisis of adulterated medicines and foods such as heparin, glycerin, and melamine. He spoke of how the US Food and Drug Administration (FDA) will now have a presence in India, in several offices. He talked about the non-government status of the United States Pharmacopeial Convention, and its unique position in the US Federal Food, Drug, and Cosmetic Act. He reinforced the importance to USP of being in India to work with the Indian industry, pharma trade associations and the government.
Reggie’s current work is to provide Executive Secretary support to WHO’s International Medical Products Anti-Counterfeiting Taskforce (IMPACT), which was created in Rome in 2006 to develop strong approaches to combat counterfeit and substandard medicines. He spoke of IMPACT ‘s five working groups that focus on national and international initiatives in areas such as legislative and regulatory infrastructure, regulatory implementation, enforcement, technology and communication. He reviewed several proposed initiatives, including recommendations for revision of Good Distribution Practices with emphasis on counterfeit medical products. He noted IMPACT’s modern testing technologies that will help combat counterfeiting and adulteration.
Gupta said that Indian pharma manufacturers are major exporters to the US and Europe. She indicated that the Ministry of Chemicals and Fertilizers is looking for joint collaborations in research and development, biologics and biotechnology, and education sectors. She emphasised that the Ministry is dedicated to the growth of the pharma industry in India.